Cencora COR, a globally recognized healthcare and pharmaceutical distributor, has been generating considerable interests amongst investors and analysts. It's been lauded as a top momentum and growth stock for the long-term. It's been outperforming other medical stocks and hitting multiple 52-week highs, suggesting an ongoing bullish trend. Experts like Jim Cramer have heralded Cencora for its successful position in the middleman drug game. The company has also been intentional in debt management as evidenced by its recent senior notes offering worth $1.8 billion. On the strategic front,
Cencora's acquisition of Retina Consultants of America for $4.6B has been finalized, leading analysts to predict a subsequent boost in 2025 EPS. Simultaneously, strategic
partnerships with the likes of Harrow are making key drugs more accessible, indicating a promising outlook. Meanwhile, despite insider sales by executives such as CEO Robert Mauch, the stock remains robust with adjustments in price targets by firms like Baird and BofA. Nevertheless, the market is closely watching for the next earnings release and Cencora's performance amidst the tariff wars.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Thu, 17 Apr 2025 18:41:44 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -5
